51
|
Di Martile M, Desideri M, Gabellini C, Eramo A, Carradori S, Secci D, Milella M, Del Bufalo D, Trisciuoglio D. 822: The histone acetyltransferases inhibitor CPTH6 preferentially inhibits proliferation of patient-derived lung cancer stem cells in vitro and in vivo. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50725-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
52
|
Chimenti F, Bizzarri B, Bolasco A, Secci D, Chimenti P, Granese A, Carradori S, Rivanera D, Zicari A, Scaltrito MM, Sisto F. Corrigendum to “Synthesis, selective anti-Helicobacter pylori activity, and cytotoxicity of novel N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides” [Bioorg. Med. Chem. Lett. 20 (2010) 4922–4926]. Bioorg Med Chem Lett 2014. [DOI: 10.1016/j.bmcl.2014.04.066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
53
|
De Monte C, Carradori S, Chimenti P, Secci D, Mannina L, Alcaro F, Petzer A, N'Da CI, Gidaro MC, Costa G, Alcaro S, Petzer JP. New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling studies. Eur J Med Chem 2014; 82:164-71. [PMID: 24904963 DOI: 10.1016/j.ejmech.2014.05.048] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2014] [Revised: 05/13/2014] [Accepted: 05/21/2014] [Indexed: 12/17/2022]
Abstract
Although there are clinical trials and in vivo studies in literature regarding the anxiolytic and antidepressant activities of the components of Crocus sativus L., their effects on the human monoamine oxidases (hMAO-A and hMAO-B), enzymes which are involved in mental disorders and neurodegenerative diseases, have not yet been investigated. We have thus examined the hMAO inhibitory activities of crocin and safranal (the most important active principles in saffron) and, subsequently, designed a series of safranal derivatives to evaluate which chemical modifications confer enhanced inhibition of the hMAO isoforms. Docking simulations were performed in order to identify key molecular recognitions of these inhibitors with both isoforms of hMAO. In this regard, different mechanisms of action were revealed. This study concludes that safranal and crocin represent useful leads for the discovery of novel hMAO inhibitors for the clinical management of psychiatric and neurodegenerative disorders.
Collapse
|
54
|
D’Ascenzio M, Carradori S, Secci D, Mannina L, Sobolev AP, De Monte C, Cirilli R, Yáñez M, Alcaro S, Ortuso F. Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors. Bioorg Med Chem 2014; 22:2887-95. [DOI: 10.1016/j.bmc.2014.03.042] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2014] [Revised: 03/21/2014] [Accepted: 03/27/2014] [Indexed: 12/26/2022]
|
55
|
Carradori S, Secci D, D'Ascenzio M, Chimenti P, Bolasco A. Microwave and Ultrasound-Assisted Synthesis of Thiosemicarbazones and Their Corresponding (4,5-Substituted-thiazol-2-yl)hydrazines. J Heterocycl Chem 2014. [DOI: 10.1002/jhet.1856] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
56
|
Secci D, Carradori S, Bizzarri B, Bolasco A, Ballario P, Patramani Z, Fragapane P, Vernarecci S, Canzonetta C, Filetici P. Synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors. Bioorg Med Chem 2014; 22:1680-9. [DOI: 10.1016/j.bmc.2014.01.022] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2013] [Revised: 12/20/2013] [Accepted: 01/16/2014] [Indexed: 10/25/2022]
|
57
|
Lenoci A, Tomassi S, Conte M, Benedetti R, Rodriguez V, Carradori S, Secci D, Castellano S, Sbardella G, Filetici P, Novellino E, Altucci L, Rotili D, Mai A. Quinoline-based p300 histone acetyltransferase inhibitors with pro-apoptotic activity in human leukemia U937 cells. ChemMedChem 2014; 9:542-8. [PMID: 24504685 DOI: 10.1002/cmdc.201300536] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2013] [Indexed: 01/27/2023]
Abstract
Chemical manipulations performed on 2-methyl-3-carbethoxyquinoline (1), a histone acetyltransferase inhibitor previously identified by our research group and active at the sub-millimolar/millimolar level, led to compounds bearing higher alkyl groups at the C2-quinoline or additional side chains at the C6-quinoline positions. Such compounds displayed at least threefold improved inhibitory potency toward p300 protein lysine acetyltransferase activity; some of them decreased histone H3 and H4 acetylation levels in U937 cells and induced high degrees of apoptosis (three compounds >10-fold higher than compound 1) after treatment of U937 cells.
Collapse
|
58
|
Materazzo S, Carradori S, Ferretti R, Gallinella B, Secci D, Cirilli R. Effect of the water content on the retention and enantioselectivity of albendazole and fenbendazole sulfoxides using amylose-based chiral stationary phases in organic–aqueous conditions. J Chromatogr A 2014; 1327:73-9. [DOI: 10.1016/j.chroma.2013.12.051] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2013] [Revised: 12/10/2013] [Accepted: 12/16/2013] [Indexed: 11/29/2022]
|
59
|
Carradori S, D'Ascenzio M, Chimenti P, Secci D, Bolasco A. Selective MAO-B inhibitors: a lesson from natural products. Mol Divers 2013; 18:219-43. [PMID: 24218136 DOI: 10.1007/s11030-013-9490-6] [Citation(s) in RCA: 92] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2013] [Accepted: 10/21/2013] [Indexed: 12/30/2022]
Abstract
Monoamine oxidases (MAOs) are mitochondrial bound enzymes, which catalyze the oxidative deamination of monoamine neurotransmitters. Inside the brain, MAOs are present in two isoforms: MAO-A and MAO-B. The activity of MAO-B is generally higher in patients affected by neurodegenerative diseases like Alzheimer's and Parkinson's. Therefore, the search for potent and selective MAO-B inhibitors is still a challenge for medicinal chemists. Nature has always been a source of inspiration for the discovery of new lead compounds. Moreover, natural medicine is a major component in all traditional medicine systems. In this review, we present the latest discoveries in the search for selective MAO-B inhibitors from natural sources. For clarity, compounds have been classified on the basis of structural analogy or source: flavonoids, xanthones, tannins, proanthocyanidins, iridoid glucosides, curcumin, alkaloids, cannabinoids, and natural sources extracts. MAO inhibition values reported in the text are not always consistent due to the high variability of MAO sources (bovine, pig, rat brain or liver, and human) and to the heterogeneity of the experimental protocols used.
Collapse
|
60
|
Chimenti P, Petzer A, Carradori S, D’Ascenzio M, Silvestri R, Alcaro S, Ortuso F, Petzer JP, Secci D. Exploring 4-substituted-2-thiazolylhydrazones from 2-, 3-, and 4-acetylpyridine as selective and reversible hMAO-B inhibitors. Eur J Med Chem 2013; 66:221-7. [DOI: 10.1016/j.ejmech.2013.05.032] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2013] [Revised: 05/20/2013] [Accepted: 05/22/2013] [Indexed: 12/24/2022]
|
61
|
Carradori S, Secci D, Bolasco A, Rivanera D, Mari E, Zicari A, Lotti LV, Bizzarri B. Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents. Eur J Med Chem 2013; 65:102-11. [DOI: 10.1016/j.ejmech.2013.04.042] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2013] [Revised: 04/24/2013] [Accepted: 04/25/2013] [Indexed: 02/07/2023]
|
62
|
Valente S, Trisciuoglio D, Tardugno M, Benedetti R, Labella D, Secci D, Mercurio C, Boggio R, Tomassi S, Di Maro S, Novellino E, Altucci L, Del Bufalo D, Mai A, Cosconati S. Cover Picture: tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells (ChemMedChem 5/2013). ChemMedChem 2013. [DOI: 10.1002/cmdc.201390015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
63
|
Valente S, Trisciuoglio D, Tardugno M, Benedetti R, Labella D, Secci D, Mercurio C, Boggio R, Tomassi S, Di Maro S, Novellino E, Altucci L, Del Bufalo D, Mai A, Cosconati S. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells. ChemMedChem 2013; 8:800-11. [PMID: 23526814 DOI: 10.1002/cmdc.201300005] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2013] [Revised: 02/16/2013] [Indexed: 12/12/2022]
Abstract
Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors. Compounds 8 b and 10 c selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-α-tubulin levels in human acute myeloid leukemia U937 cells. In the same cell line, compounds 8 b and 10 c elicited 18.4 and 21.4 % apoptosis, respectively (SAHA: 16.9 %), and the pyrrole anilide 9 c displayed the highest cytodifferentiating effect (90.9 %). In tests against a wide range of various cancer cell lines to determine its antiproliferative effects, compound 10 c exhibited growth inhibition from sub-micromolar (neuroblastoma LAN-5 and SH-SY5Y cells, chronic myeloid leukemia K562 cells) to low-micromolar (lung H1299 and A549, colon HCT116 and HT29 cancer cells) concentrations. In HT29 cells, 10 c increased histone H3 acetylation, and decreased the colony-forming potential of the cancer cells by up to 60 %.
Collapse
|
64
|
Ragazzoni Y, Desideri M, Gabellini C, De Luca T, Carradori S, Secci D, Nescatelli R, Candiloro A, Condello M, Meschini S, Del Bufalo D, Trisciuoglio D. The thiazole derivative CPTH6 impairs autophagy. Cell Death Dis 2013; 4:e524. [PMID: 23470531 PMCID: PMC3613831 DOI: 10.1038/cddis.2013.53] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2012] [Revised: 01/29/2013] [Accepted: 01/31/2013] [Indexed: 12/14/2022]
Abstract
We have previously demonstrated that the thiazole derivative 3-methylcyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl]hydrazone (CPTH6) induces apoptosis and cell cycle arrest in human leukemia cells. The aim of this study was to evaluate whether CPTH6 is able to affect autophagy. By using several human tumor cell lines with different origins we demonstrated that CPTH6 treatment induced, in a dose-dependent manner, a significant increase in autophagic features, as imaged by electron microscopy, immunoblotting analysis of membrane-bound form of microtubule-associated protein 1 light chain 3 (LC3B-II) levels and by appearance of typical LC3B-II-associated autophagosomal puncta. To gain insights into the molecular mechanisms of elevated markers of autophagy induced by CPTH6 treatment, we silenced the expression of several proteins acting at different steps of autophagy. We found that the effect of CPTH6 on autophagy developed through a noncanonical mechanism that did not require beclin-1-dependent nucleation, but involved Atg-7-mediated elongation of autophagosomal membranes. Strikingly, a combined treatment of CPTH6 with late-stage autophagy inhibitors, such as chloroquine and bafilomycin A1, demonstrates that under basal condition CPTH6 reduces autophagosome turnover through an impairment of their degradation pathway, rather than enhancing autophagosome formation, as confirmed by immunofluorescence experiments. According to these results, CPTH6-induced enhancement of autophagy substrate p62 and NBR1 protein levels confirms a blockage of autophagic cargo degradation. In addition, CPTH6 inhibited autophagosome maturation and compounds having high structural similarities with CPTH6 produced similar effects on the autophagic pathway. Finally, the evidence that CPTH6 treatment decreased α-tubulin acetylation and failed to increase autophagic markers in cells in which acetyltransferase ATAT1 expression was silenced indicates a possible role of α-tubulin acetylation in CPTH6-induced alteration in autophagy. Overall, CPTH6 could be a valuable agent for the treatment of cancer and should be further studied as a possible antineoplastic agent.
Collapse
|
65
|
Secci D, Carradori S, Bolasco A, Bizzarri B, D’Ascenzio M, Maccioni E. Discovery and Optimization of Pyrazoline Derivatives As Promising Monoamine Oxidase Inhibitors. Curr Top Med Chem 2013. [DOI: 10.2174/1568026611212200009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
66
|
Carradori S, Cristini C, Secci D, Gulia C, Gentile V, Di Pierro GB. Current and emerging strategies in bladder cancer. Anticancer Agents Med Chem 2013; 12:589-603. [PMID: 22043990 DOI: 10.2174/187152012800617768] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2011] [Revised: 10/06/2011] [Accepted: 10/09/2011] [Indexed: 11/22/2022]
Abstract
Urothelial cell carcinoma is one of the most common malignancies of the urinary tract. The standard of care, intravesical chemo- and immunotherapy, while effective, is associated with a considerable side-effect profile and approximately 30% of patients either fail to respond to treatment or suffer recurrent disease within 5 years. In the setting of muscle-invasive urothelial carcinoma, use of neoadjuvant chemotherapy is associated with overall survival benefit. Muscle invasive bladder cancer is life threatening, showing modest chemosensitivity, and usually requires radical cystectomy. Although bladder cancer is fairly well-genetically characterized, clinical trials with molecularly targeted agents have, in comparison to other solid tumors, been few in number and largely unsuccessful. Hence, bladder cancer represents a considerable opportunity and challenge for alternative therapies. In this review, we will focus on promising global or pathway-based approaches (epigenetic modulators, kinase inhibitors, angiogenesis blockage, peroxisome proliferator-activated receptor γ agonists, apoptosis inductors, virus therapy) supported by a deeper understanding of molecular biology of urothelial carcinoma, which have been recently tested in clinical trials.
Collapse
|
67
|
Carradori S, Cirilli R, Dei Cicchi S, Ferretti R, Menta S, Pierini M, Secci D. 3-Methylcyclohexanone thiosemicarbazone: Determination of E/Z isomerization barrier by dynamic high-performance liquid chromatography, configuration assignment and theoretical study of the mechanisms involved by the spontaneous, acid and base catalyzed processes. J Chromatogr A 2012; 1269:168-77. [DOI: 10.1016/j.chroma.2012.08.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 07/20/2012] [Accepted: 08/02/2012] [Indexed: 11/16/2022]
|
68
|
Secci D, Bolasco A, Carradori S, D'Ascenzio M, Nescatelli R, Yáñez M. Recent advances in the development of selective human MAO-B inhibitors: (Hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines. Eur J Med Chem 2012; 58:405-17. [DOI: 10.1016/j.ejmech.2012.10.032] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Revised: 10/17/2012] [Accepted: 10/18/2012] [Indexed: 12/29/2022]
|
69
|
Secci D, Bolasco A, D'Ascenzio M, della Sala F, Yáñez M, Carradori S. Conventional and Microwave-Assisted Synthesis of Benzimidazole Derivatives and TheirIn VitroInhibition of Human Cyclooxygenase. J Heterocycl Chem 2012. [DOI: 10.1002/jhet.1058] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
70
|
Carradori S, D'Ascenzio M, De Monte C, Secci D, Yáñez M. Synthesis and Selective Human Monoamine Oxidase B Inhibition of Heterocyclic Hybrids Based on Hydrazine and Thiazole Scaffolds. Arch Pharm (Weinheim) 2012; 346:17-22. [DOI: 10.1002/ardp.201200318] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 09/12/2012] [Accepted: 09/19/2012] [Indexed: 01/06/2023]
|
71
|
Secci D, Carradori S, Bolasco A, Bizzarri B, D'Ascenzio M, Maccioni E. Discovery and Optimization of Pyrazoline Derivatives As Promising Monoamine Oxidase Inhibitors. Curr Top Med Chem 2012; 12:2240-57. [DOI: 10.2174/156802612805220057] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Revised: 07/13/2012] [Accepted: 07/13/2012] [Indexed: 11/22/2022]
|
72
|
Carradori S, Secci D, Bolasco A, De Monte C, Yáñez M. Synthesis and selective inhibitory activity against human COX-1 of novel 1-(4-substituted-thiazol-2-yl)-3,5-di(hetero)aryl-pyrazoline derivatives. Arch Pharm (Weinheim) 2012; 345:973-9. [PMID: 22961586 DOI: 10.1002/ardp.201200249] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2012] [Revised: 07/23/2012] [Accepted: 07/24/2012] [Indexed: 11/12/2022]
Abstract
Novel 1-(4-ethyl carboxylate-thiazol-2-yl)-3,5-di(hetero)aryl-2-pyrazoline derivatives were obtained by reacting 3,5-di(hetero)aryl-1-thiocarbamoyl-2-pyrazolines with the ethyl ester of α-bromo-pyruvic acid. The synthesized compounds were confirmed by spectroscopic data and assayed to evaluate their in vitro ability to inhibit both isoforms of human cyclooxygenase (hCOX). Some derivatives (compounds 5, 6, 13, 16, and 17) displayed promising selectivity against hCOX-1 in the micromolar range and were shown to have a selectivity index similar or better than the reference drugs (indometacin, diclofenac). The introduction of a phenyl or a 4-F-phenyl ring on the C5 associated with a 4-substituted phenyl or a heteroaryl group on the C3 of (4-substituted-thiazol-2-yl)pyrazoline derivatives improved the activity against hCOX-1. Thanks to these preliminary results it could be possible to extend our knowledge of the pharmacophoric requirements for the discovery of new pyrazoline-based hCOX-1 inhibitors.
Collapse
|
73
|
Carradori S, Secci D, Bolasco A, Chimenti P, D'Ascenzio M. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2012; 22:759-801. [DOI: 10.1517/13543776.2012.698613] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
74
|
Secci D, Bolasco A, Chimenti P, Carradori S. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents. Curr Med Chem 2012; 18:5114-44. [PMID: 22050759 DOI: 10.2174/092986711797636090] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2011] [Revised: 08/02/2011] [Accepted: 08/04/2011] [Indexed: 11/22/2022]
Abstract
Monoamine oxidase plays a significant role in the control of intracellular concentration of monoaminergic neurotransmitters or neuromodulators and dietary amines. The rapid degradation of these molecules ensures the proper functioning of synaptic neurotransmission and is critically important for the regulation of emotional and other brain functions. The development of human MAO inhibitors led to important breakthroughs in the therapy of several neuropsychiatric disorders. Different families of heterocycles containing 2 or 4 nitrogen atoms have been used as scaffolds for synthesizing selective monoamine oxidase inhibitors, but the early period of the MAO-inhibitors started with hydrazine derivatives. Pyrazole, pyrazoline, and pyrazolidine derivatives can be considered as a cyclic hydrazine moiety. This scaffold also displayed promising antidepressant and anticonvulsant properties as demonstrated by different and established animal models. Diversely substituted pyrazoles, embedded with a variety of functional groups, are important biological agents and a significant amount of research activity has been directed towards this chemical class.
Collapse
|
75
|
Gabellini C, Ragazzoni Y, Desideri M, Nescatelli R, Carradori S, Secci D, Trisciuoglio D, Bufalo DD. Abstract LB-82: Modulation of autophagic flux by CPTH6, a Gcn5/pCAF histone acetyltransferase inhibitor with antitumoral activity. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-lb-82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The thiazole-derivative 3-methylcyclopentilidene-[4-(4′-chlorophenyl)thiazol-2-yl]hydrazone (CPTH6) is a Gcn5 and pCAF histone acetyltransferases inhibitor that induces apoptosis and cell cycle arrest in human leukemia cells. The aim of this study was to evaluate whether CPTH6-induced apoptosis is associated with other cell death mechanisms, such as autophagy. Herein, we show that CPTH6 interferes with autophagic flux in several human tumor cell lines of different origin. CPTH6 treatment increases microtubule-associated protein 1 light chain 3-II (LC3-II) levels and induces the appearance of typical LC3-II- associated autophagosomal puncta in a time- and dose-dependent manner. Moreover, this compound decreases the expression of autophagy promoting proteins beclin1, Atg5 and Atg12. Strikingly, combined treatment of CPTH6 with bafilomycin A1, a proton ATPase inhibitor, demonstrates that CPTH6 reduces autophagosomes turnover, through an impairment of their degradation pathway, rather than enhancing autophagosomes formation. According to these results, CPTH6 treatment enhances p62/SQSTM1 protein levels in several tumor cell lines, indicating a blockage of autophagic cargo degradation. CPTH6 also reduces the phosphorylation of several components of transduction signalling pathways, such as Akt, 4E-BP1 and eIF4E, ERK1/2 and GSK-3α/β while it activates p38 MAPK pathway. In vivo CPTH6 exposure does not produce any adverse effects on health in mice as monitored by diet consumption, body-weight loss, postural and behavioral changes. Most importantly, CPTH6 exerts antitumoral effect on U937 human leukemia xenografts. These findings demonstrate that CPTH6 induces apoptosis and interferes with autophagic flux in human cancer cells, supporting further exploration of CPTH6 and related molecules as potential anticancer agents.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-82. doi:1538-7445.AM2012-LB-82
Collapse
|